Form D · Pharmaceuticals
NeuroRx, Inc.
Wilmington, DE · CIK 0001679768
Offering snapshot reported Nov 23, 2016 · SEC filing
- Reported sold
- $4.54M Offering amount: $5.54M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $40K Reported outside-investor minimum
- First sale
- Nov 10, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 23, 2016 | Initial | $4,541,991 | No comparison | 11 | SEC filing |
| Nov 23, 2016 | Initial | $2,159,687 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275112
Source: Form D, filed Nov 23, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sherry Glied | Director |
| Chaim Hurvitz | Director |
| Jonathan Javitt | Director, Executive |
| Daniel Javitt | Director |
| James Lawrence | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1201 Orange Street, Suite 600 One Commerce Center
Wilmington, DE, 19801
Wilmington, DE, 19801